First Tracks Biotherapeutics (HAM:B43) Other Current Receivables: €0.00 Mil (As of Dec. 2024)


HAM:B43 First Tracks Biotherapeutics Inc HAM:B43
20 GF Score
Price €32.00
! 3 Warning Signs
View Full Analysis

What is First Tracks Biotherapeutics Other Current Receivables?

First Tracks Biotherapeutics HAM:B43 +29.29% 20 Other Current Receivables is €0.00 Mil as of Dec. 2024. GuruFocus rates HAM:B43 with a GF Score™ of 20/100. The stock has 3 warning signs investors should review.

First Tracks Biotherapeutics's Other Current Receivables for the quarter that ended in Dec. 2024 was €0.00 Mil.

First Tracks Biotherapeutics Other Current Receivables Related Terms

First Tracks Biotherapeutics Other Current Receivables Historical Data

* Premium members only.

The historical data trend for First Tracks Biotherapeutics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

First Tracks Biotherapeutics Other Current Receivables Chart

First Tracks Biotherapeutics Annual Data
Trend Dec23 Dec24
Other Current Receivables
0.00 0.00

First Tracks Biotherapeutics Semi-Annual Data
Dec23 Dec24
Other Current Receivables 0.00 0.00
HAM:B43
20GF Score
First Tracks Biotherapeutics Inc HAM:B43
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

First Tracks Biotherapeutics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €0.00 Mil mean?
First Tracks Biotherapeutics (HAM:B43) has a Other Current Receivables of €0.00 Mil as of Dec. 2024. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on First Tracks Biotherapeutics and its competitors.
Is First Tracks Biotherapeutics' Other Current Receivables too high?
First Tracks Biotherapeutics' current Other Current Receivables is €0.00 Mil. Overall, First Tracks Biotherapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' Other Current Receivables compare to ALT and RGNX?
First Tracks Biotherapeutics' Other Current Receivables of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on First Tracks Biotherapeutics and its competitors. First Tracks Biotherapeutics's current Other Current Receivables is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (HAM:B43) has a current Other Current Receivables of €0.00 Mil. The current Other Current Receivables is €0.00 Mil. First Tracks Biotherapeutics' overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For First Tracks Biotherapeutics (HAM:B43), the current Other Current Receivables is €0.00 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

First Tracks Biotherapeutics Business Description

Other Exchanges TRAX:USA
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
20GF Score

Get the complete analysis for HAM:B43

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€32.00
Price